Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 19/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2634966 | 0.89 | GPR119 (0.52) | GPR119CYP2C9CYP3A4KCNH2 | |
| SCHEMBL13050756 | 0.88 | GPR119 (0.71) | GPR119CYP2C9CYP3A4KCNH2 | |
| SCHEMBL1060691 | 0.88 | GPR119 (0.58) | GPR119CYP2C9CYP3A4KCNH2 | |
| SCHEMBL1061381 | 0.87 | GPR119 (0.56) | GPR119CYP2C9CYP3A4KCNH2 | |
| SCHEMBL1061052 | 0.86 | GPR119 (0.62) | GPR119CYP2C9KCNH2 | |
| SCHEMBL12961780 | 0.84 | GPR119 (0.67) | GPR119CYP2C9CYP3A4KCNH2 | |
| SCHEMBL1056240 | 0.84 | GPR119 (0.55) | GPR119CYP2C9KCNH2 | |
| SCHEMBL1060873 | 0.83 | GPR119 (0.58) | GPR119CYP2C9CYP3A4KCNH2 | |
| SCHEMBL1053663 | 0.81 | GPR119 (0.56) | GPR119CYP2C9KCNH2 | |
| SCHEMBL1059905 | 0.80 | GPR119 (0.47) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2438051-A1 | L- ( PIPERIDIN-4-YL) -PYRAZOLE DERIVATIVES AS GPR 119 MODULATORS | Pfizer Inc. (US) | 2012-04-11 | — | — | EP | claimed |
| US-20110020460-A1 | GPR 119 MODULATORS | PFIZER INC. | 2011-01-27 | — | — | US | claimed |
| WO-2010140092-A1 | L- ( PIPERIDIN-4-YL) -PYRAZOLE DERIVATIVES AS GPR 119 MODULATORS | PFIZER INC. (US) | 2010-12-09 | — | — | WO | claimed |
| US-20110020460-A1 | GPR 119 MODULATORS | PFIZER INC. | 2011-01-27 | — | — | US | disclosed |
| US-20110020460-A1 | GPR 119 MODULATORS | PFIZER INC. | 2011-01-27 | — | — | US | disclosed |
| US-20110020460-A1 | GPR 119 MODULATORS | PFIZER INC. | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110020460-A1 | GPR 119 MODULATORS | GPR119, GPR65, GPR88 | GPR119 1/4885CYP2C9 1510/4885CYP3A4 2087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.